Fierce Healthcare

FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELS

As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing reports of ...
Monthly Prescribing Reference

FDA approves MixJect system for Trelstar

MixJect, a drug delivery system, has been approved for use with Watson’s Trelstar Depot and Trelstar LA (triptorelin pamoate injectable suspension). MixJect features a smaller 21-gauge needle, ...
Medscape

FDA Approves 6-Month Formulation of Triptorelin for Prostate Cancer

March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...
Medindia

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer

MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. Food and Drug Administration (FDA) approval of ...
Medindia

Side effect(s) of Triptorelin

Review the side-effects of Triptorelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Renal & Urology News

FDA Clears a Six-Month Trelstar Formulation

Watson Pharmaceuticals has received FDA approval of Trelstar (triptorelin pamoate for injectable suspension) 22.5 mg, the first and only six-month intramuscular gonadotropin releasing hormone (GnRH) ...